Search

Your search keyword '"Oberlin, O"' showing total 322 results
Start Over Author "Oberlin, O" Language english
322 results on '"Oberlin, O"'

1. Suture versus open mesh repair for small umbilical hernia: Results of a propensity-matched cohort study

Author

Antor, M., Beck, M., Barrat, C., Berney, C., Binot, D., Bousquet, J., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Chollet, J.-M., Cossa, J.-P., Dabrowski, A., Delaunay, T., Démaret, S., Drissi, F., Demian, H., Dubuisson, V., Dugue, T., Fromont, G., Gillion, J.-F., Jacquin, C., Jurczak, F., Khalil, H., Launay-Savary, M., Lepère, M., Lépront, D., Longeville, J.H., Le Toux, N., Loriau, J., Magne, E., Ngo, P., Oberlin, O., Passot, G., Pavis d’Escurac, X., Putinier, J.B., Renard, Y., Romain, B., Soler, M., Roos, S., Thillois, J.-M., Tiry, P., Vu, P., Verhaeghe, R., Warlaumont, M., Zaranis, C., Frey, Samuel, Beauvais, Adrien, Soler, Marc, Beck, Mathieu, Dugué, Timothée, Pavis d’Escurac, Xavier, Dabrowski, André, Jurczak, Florent, and Gillion, Jean-François

Published
2023
Full Text
View/download PDF

2. Functional outcomes in symptomatic versus asymptomatic patients undergoing incisional hernia repair: Replacing one problem with another? A prospective cohort study in 1312 patients

Author

Abet, E., Ain, J.-F., Arnalsteen, L., Baraket, O., Beck, M., Bellouard, A., Benizri, E., Berney, C., Bilem, D., Binot, D., Blanc, B., Blazquez, D., Bonan, A., Boukortt, T., Brehant, O., Cas, O., Champault-Fezais, A., Chau, A., Chollet, J.-M., Constantin, M., Cossa, J.-P., Dabrowski, A., David, A., Demaret, S., Dubuisson, V., Dugue, T., El Nakadi, I., Faure, J.-P., Frileux, P., Fromont, G., Gadiri, N., Gillion, J.-F., Glehen, O., Hennequin, S., Isambert, M., Jurczak, F., Khalil, H., Lamblin, A., Largenton, C., Lavy, M., Lepère, M., Le Toux, N., Magne, E., Manfredelli, S., Mariette, C., Marion, Y., Mercoli, H.-A., Mesli Smain, N., Moszkowicz, D., Najim, M., Oberlin, O., Odet, E., Ortega Deballon, P., Pavis d’Escurac, X., Pichot Delahaye, V., Putinier, J.B., Regimbeau, J.M., Renard, Y., Romain, B., Rouquie, D., Soler, M., Soufron, J., Roos, S., Thillois, J.-M., Tiry, P., Vauchaussade De Chaumont, A., Vinatier, E., Vu, P., Verhaeghe, R., Zaranis, C., Zeineb, M., de Smet, Gijs H.J., Sneiders, Dimitri, Yurtkap, Yagmur, Menon, Anand G., Jeekel, Johannes, Kleinrensink, Gert-Jan, Lange, Johan F., and Gillion, Jean-François

Published
2020
Full Text
View/download PDF

4. External Validation of the European Hernia Society Classification for Postoperative Complications after Incisional Hernia Repair: A Cohort Study of 2,191 Patients

Author

Ain, J.-F., Beck, M., Barrat, C., Berney, C., Berrod, J.-L., Binot, D., Boudet, M.-J., Bousquet, J., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Cardin, J.-L., Chollet, J.-M., Cossa, J.-P., Dabrowski, A., Démaret, S., Drissi, F., Durou, J., Dugue, T., Faure, J.-P., Framery, D., Fromont, G., Gainant, A., Gauduchon, L., Genser, L., Gillion, J.-F., Guillaud, A., Jacquin, C., Jurczak, F., Khalil, H., Lacroix, A., Ledaguenel, P., Lepère, M., Lépront, D., Letoux, N., Loriau, J., Magne, E., Ngo, P., Oberlin, O., Paterne, D., Pavis d'Escurac, X., Potiron, L., Renard, Y., Soler, M., Rignier, P., Roos, S., Thillois, J.-M., Tiry, P., Verhaeghe, R., Vu, P., Zaranis, C., Kroese, Leonard F., Kleinrensink, Gert-Jan, Lange, Johan F., and Gillion, Jean-Francois

Published
2018
Full Text
View/download PDF

12. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

Author

Bellera, C. A., Penel, N., Ouali, M., Bonvalot, S., Casali, P. G., Nielsen, O. S., Delannes, M., Litière, S., Bonnetain, F., Dabakuyo, T. S., Benjamin, R. S., Blay, J.-Y., Bui, B. N., Collin, F., Delaney, T. F., Duffaud, F., Filleron, T., Fiore, M., Gelderblom, H., George, S., Grimer, R., Grosclaude, P., Gronchi, A., Haas, R., Hohenberger, P., Issels, R., Italiano, A., Jooste, V., Krarup-Hansen, A., Le Péchoux, C., Mussi, C., Oberlin, O., Patel, S., Piperno-Neumann, S., Raut, C., Ray-Coquard, I., Rutkowski, P., Schuetze, S., Sleijfer, S., Stoeckle, E., Van Glabbeke, M., Woll, P., Gourgou-Bourgade, S., and Mathoulin-Pélissier, S.

Published
2015
Full Text
View/download PDF

33. Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups

Author

Minard-Colin, V, Walterhouse, D, Bisogno, G, Martelli, H, Anderson, J, Rodeberg, Da, Ferrari, A, Jenney, M, Wolden, S, De Salvo, G, Arndt, C, Merks, Jhm, Gallego, S, Schwob, D, Haie-Meder, C, Bergeron, C, Stevens, Mcg, Oberlin, O, Hawkins, D, International Society of Pediatric Oncology Sarcoma Committee, the Children's Oncology Group, the Italian Cooperative Soft Tissue Sarcoma Group, and the European pediatric Soft tissue sarcoma Study, Group., Paediatric Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
genetic structures, medicine.medical_treatment, Uterus, Uterine Cervical Neoplasms, Kaplan-Meier Estimate, Pediatrics, Gynecologic Surgical Procedures, 0302 clinical medicine, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Multicenter Studies as Topic, Child, Rhabdomyosarcoma, Clinical Trials as Topic, Univariate analysis, 030219 obstetrics & reproductive medicine, Soft tissue sarcoma, Remission Induction, Hematology, Perinatology and Child Health, Prognosis, Combined Modality Therapy, Progression-Free Survival, Treatment Outcome, medicine.anatomical_structure, vagina, Oncology, Child, Preschool, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Uterine Neoplasms, Vagina, Female, medicine.medical_specialty, Vaginal Neoplasms, Adolescent, Brachytherapy, brachytherapy, Urology, children, genital tract, radiotherapy, rhabdomyosarcoma, Pediatrics, Perinatology and Child Health, Article, 03 medical and health sciences, medicine, Humans, Radical surgery, business.industry, medicine.disease, Radiation therapy, business
Abstract

Background: Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed. Procedure: From 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n = 160), 2.7 for uterus corpus (n = 26), and 13.5 for uterus cervix (n = 51). Twenty-eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG). Results: Ten-year event-free (EFS) and overall survival (OS) were 74% (95% CI, 67–79%) and 92% (95% CI, 88–96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P = 0.08), there was no difference in OS (94% without RT vs. 89% with RT; P = 0.18). Local control using brachytherapy was excellent (93%). Fifty-one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery. Conclusions: About half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy.

Published
2018

37. Laparoscopic robot-assisted right colectomy with intracorporeal hand-sewn anastomosis.

Author

D'Annunzio, E., Oberlin, O., Goasguen, N., Lupinacci, R.M., and Valverde, A.

Subjects
COLECTOMY, LAPAROSCOPIC surgery, MESENTERIC veins
Abstract

Most operators perform the ileo-colic anastomosis extracorporeally because the manual intra-abdominal anastomosis technique is more difficult. Two trocars are then added for the assistant's use; these are always placed behind the robot trocars: a 12mm trocar in the left iliac fossa (between optical and R2 trocars) and a 5mm at the level of the left flank (between optical and R1 trocars). Graph 8 Performing manual intracorporeal side-to-side ileo-colic anastomosis, iso- or aniso-perista... The ileum and colon are opened along the antimesenteric border with monopolar scissors via the R1 arm. [Extracted from the article]

Published
2020
Full Text
View/download PDF

45. Impact of EWS-ETS Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-EWING 99 Trial

Author

Deley, M.C. le, Delattre, O., Schaefer, K.L., Burchill, S.A., Koehler, G., Hogendoorn, P.C.W., Lion, T., Poremba, C., Marandet, J., Ballet, S., Pierron, G., Brownhill, S.C., Nesslbock, M., Ranft, A., Dirksen, U., Oberlin, O., Lewis, I.J., Craft, A.W., Jurgens, H., and Kovar, H.

Subjects
chromosome-translocation sarcoma translocation gene fusions dna-binding ews-fli1 family expression proteins fuses time
Abstract

Purpose EWS-ETS fusion genes are the driving force in Ewing's sarcoma pathogenesis. Because of the variable breakpoint locations in the involved genes, there is heterogeneity in fusion RNA and protein architecture. Since previous retrospective studies suggested prognostic differences among patients expressing different EWS-FLI1 fusion types, the impact of fusion RNA architecture on disease progression and relapse was studied prospectively within the Euro-E. W. I. N. G. 99 clinical trial. Patients and Methods Among 1,957 patients who registered before January 1, 2007, 703 primary tumors were accessible for the molecular biology study. Fusion type was assessed by polymerase chain reaction on frozen (n = 578) or paraffin-embedded materials (n = 125). The primary end point was the time to disease progression or relapse. Results After exclusion of noninformative patients, 565 patients were entered into the prognostic factor analysis comparing type 1 (n = 296), type 2 (n = 133), nontype 1/nontype 2 EWS-FLI1 (n = 91) and EWS-ERG fusions (n = 45). Median follow-up time was 4.5 years. The distribution of sex, age, tumor volume, tumor site, disease extension, or histologic response did not differ between the four fusion type groups. We did not observe any significant prognostic value of the fusion type on the risk of progression or relapse. The only slight difference was that the risk of progression or relapse associated with nontype 1/nontype 2 EWS-FLI1 fusions was 1.38 (95% CI, 0.96 to 2.0) times higher than risk associated with other fusion types, but it was not significant (P = .10). Conclusion In contrast to retrospective studies, the prospective evaluation did not confirm a prognostic benefit for type 1 EWS-FLI1 fusions. J Clin Oncol 28: 1982-1988. (C) 2010 by American Society of Clinical Oncology

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results